At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
YPL-001 80 mg +2 moredrug
Likely dose
YPL-001 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo Controlled, Multicenter 2a Study to Assess Safety, Daily Respiratory Symptoms, PK, and Biomarker Variations After Administration of Either YPL-001, or Placebo in Patients With Moderate-to-Severe COPD.
In Brief
A Phase 2 clinical trial evaluating YPL-001 80 mg, YPL-001 160 mg, and 1 other intervention for Chronic Obstructive Pulmonary Disease. Completed, enrolled 61 participants across 4 sites.
Detailed Summary
This is a Phase 2a, proof-of-concept, multicenter, randomized, double-blind, double dummy, 3-treatment, parallel study, with low and high YPL 001 doses (low dose and high dose twice daily \[BID\]) and a placebo control in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartJun 2015
Primary CompletionNov 2017
TodayJul 2026
First PostedOct 23, 2014
Enrollment StartJun 4, 2015
Primary CompletionNov 8, 2017
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 11.7 years ago
Interventions
YPL-001 80 mgdrug
twice daily \[BID\]
YPL-001 160 mgdrug
twice daily \[BID\]
Placebodrug
twice daily \[BID\]